Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97
Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.
Read original at benzingaStocks · News reference
8-K filing — Structure Therapeutics Inc. (GPCR)
Filed: 2026-08-06 AccNo: 0001104659-26-092017 Size: 357 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 6, 2026, 8:13 PM
- Checked
- Aug 6, 2026, 8:13 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.
Read original at benzingaLess Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.
Read original at benzinga